Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2024-02-27 00:00:00 ET · period of report 2024-02-23 · accession 0000875320-24-000095 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-27 | 2024-02-26 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $425.70 | -4,239 | 25.8K | -14% | -$1.80M | |
| 2024-02-27 | 2024-02-23 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | F - Tax | $431.79 | -3,970 | 30.1K | -12% | -$1.71M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-26 | S | D | 4,239 | $425.70 | 25,813 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-23 | F | D | 3,970 | $431.79 | 30,052 | D | — | — |